# Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension

> **NCT04780932** · PHASE2,PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 96 (actual)

## Conditions studied

- Thromboembolic Pulmonary Hypertension
- Chronic Disease
- Inoperable Disease

## Interventions

- **DRUG:** Macitentan 10mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04780932
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-14
- **Primary completion:** 2025-07-03
- **Final completion:** 2025-07-03
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2025-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04780932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04780932, "Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04780932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*